A college sprinter was stabbed to death in Missouri, and his girlfriend is behind bars for allegedly committing the act, according to multiple reports. Lincoln University track and field athlete ...

An exploration of what’s driving a change in America’s parking lots. An exploration of what’s driving a change in America’s parking lots. In 2020, AAA updated its curriculum to advise drivers to back ...

Bad Bunny sounded way different with no music. It has been days since Bad Bunny hit the stage inside Levi’s Stadium. The conversation around him has not died down. For the millions who tuned in to ...

Blink, and you just might miss all the short track speed skating events at this year's Winter Olympics. Not to be confused with traditional speed skating, short track varies by rules, format and event ...

With the new year under way, the prospect of lower interest rates has been overwhelmed by geopolitical chaos. Confidence therefore still feels fragile. That backdrop is shaping how brokers think about ...

Access to education is widely recognised as a fundamental human right and one of the strongest drivers of upward socio-economic mobility. It offers individuals a pathway out of poverty, equips ...

⚠️ Middle East tensions = Portfolio impacts. Know your exposure NOW Ask WarrenAI Bitdeer reports 251% increase in bitcoin production, expands AI cloud By Company News Published 12/15/2025, 07:39 AM ...

Subscribe to Marlin magazine and get a year of highly collectible, keepsake editions – plus access to the digital edition and archives. Sign up for the free Marlin email newsletter. When we look at ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million. The California ...

President Donald Trump is now openly embracing the conservative blueprint he desperately tried to distance himself from during the 2024 campaign. 365 Bloor Street ...

UBS recently reaffirmed its positive outlook on Ascendis Pharma following the release of competitor MBX’s clinical data for persistent hypoparathyroidism, highlighting Ascendis’s Yorvipath therapy ...